35217-95-9

Usage

Uses

Used in Organic Synthesis:
4-OXIRANYLMETHOXY-BENZOIC ACID is used as a key intermediate in organic synthesis for the production of various chemical compounds. Its unique structure allows for versatile reactions and transformations, making it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-OXIRANYLMETHOXY-BENZOIC ACID is used as a starting material for the development of new drugs. Its potential biological and pharmacological effects, such as anti-inflammatory and anti-cancer properties, make it a promising candidate for the treatment of various diseases and conditions.
Used in Anti-Inflammatory Applications:
4-OXIRANYLMETHOXY-BENZOIC ACID is used as an anti-inflammatory agent in pharmaceutical research. Its ability to modulate inflammatory pathways and reduce inflammation makes it a potential therapeutic option for conditions characterized by excessive inflammation, such as arthritis, asthma, and inflammatory bowel disease.
Used in Anti-Cancer Applications:
4-OXIRANYLMETHOXY-BENZOIC ACID is also used as an anti-cancer agent in pharmaceutical research. Its potential to inhibit cancer cell growth and proliferation, as well as its ability to induce apoptosis in cancer cells, positions it as a candidate for the development of novel cancer therapies.
Used in Drug Development:
4-OXIRANYLMETHOXY-BENZOIC ACID is utilized in drug development to explore its potential as a lead compound for the creation of new pharmaceuticals. Its unique chemical properties and biological activities make it a valuable tool in the discovery and optimization of new drugs for various therapeutic areas.

Upstream product

• 106-89-8 epichlorohydrin 
• 99-96-7 4-hydroxy-benzoic acid 
• 50625-94-0 ethyl 4-(glycidyloxy)benzoate 
• 5535-03-5 methyl rac-4-(oxiran-2-ylmethoxy)benzoate 
• 14697-49-5 4-(2,3-epoxy)propyloxybenzaldehyde 
• 123-08-0 4-hydroxy-benzaldehyde 
• 2345-34-8 4-acetyloxy-benzoic acid 
• 3132-64-7 1,2-Epoxy-3-bromopropane 
• 2186-24-5 cresyl-glicidyl ether 

Downstream Products

• 147538-71-4 2-[3-[(p-carboxy)-phenoxy]-2-hydroxy-propylthio]-benzothiazole 
• 1165820-52-9 C₇₅H₁₁₉N₅O₃₇ 

Relevant academic research and scientific papers

Stepwise benzylic oxygenation via uranyl-photocatalysis

Stepwise oxygenation at the benzylic position (1°, 2°, 3°) of aromatic molecules was comprehensively established under ambient conditions via uranyl photocatalysis to produce carboxylic acids, ketones, and alcohols, respectively. The accuracy of the stepwise oxygenation was ensured by the tunability of catalytic activity in uranyl photocatalysis, which was adjusted by solvents and additives demonstrated through Stern–Volmer analysis. Hydrogen atom transfer between the benzylic position and the uranyl catalyst facilitated oxygenation, further confirmed by kinetic studies. Considerably improved efficiency of flow operation demonstrated the potential for industrial synthetic application.

COMPOUND APPLICABLE TO PHOTOALIGNMENT METHOD AND ITS PHOTOSENSITIVE POLYMER

PURPOSE: A photosensitive polymer prepared by polymerizing a compound which is proper for photoalignment is provided to prevent static electricity and to manufacture liquid crystal alignment film with high optical uniformity. CONSTITUTION: A compound which is proper to photoalignment is denoted by chemical formula 1. A photosensitive polymer is used by polymerizing the compound of chemical formula 1. A liquid crystal alignment film is manufactured using the photoalignment agent. A liquid crystal display device is manufactured using the photoalignment agent.

Crystal structures of 4-(oxiran-2-ylmethoxy) benzoic acid and 4-acetoxybenzoic acid

Compounds 4-(oxiran-2-ylmethoxy)benzoic acid (2) and 4-acetoxybenzoic acid (4) are synthesized by a new synthetic route and studied by X-ray crystallography. Compound 2 crystallizes in the monoclinic system, P21/n space group, a = 5.1209(2) A, b = 30.3429(16) A, c = 5.9153(3) A, β = 96.725(3)°, V = 912.81(8) A3, Z = 4. Compound 4 crystallizes in the triclinic system, P-1 space group, a = 7.3400(4) A, b = 8.0819(3) A, c = 15.6548(9) A, α = 85.754(3)°, β = 84.268(2)°, γ = 70.023(3)°, V = 867.63(8) A3, Z = 4. The crystal structure of 2 comprises two crystallographically independent molecules of the compound. In the crystal structures of 2 and 4, pairs of molecules form carboxyl dimers. Original Russian Text Copyright

Facile synthesis of second-generation dendrons with an orthogonal functional group at the focal point

Facile synthesis of second-generation dendrons with an aldehyde, epoxy, or t-Boc group at the focal point and nine carboxylic acid groups at the periphery is reported. The scheme includes a coupling of the first-generation dendrons and a two-step, one-pot reaction that proceeds through a Boc deprotection and in situ conjugation at the focal point.

8-Substituted purine derivatives: a new class of lipid-lowering agents

A series of purine derivatives have been prepared and their in vivo abilities to lower plasma total cholesterol and triglyceride levels, and to elevate high density lipoprotein (HDL) cholesterol levels in hyperlipemic rats have been tested.Some compounds, among which 8-propylthio>adenosine 31, 8--2-oxopropylthio>adenosine 33 and 8--2-hydrazonecarboxamidepropylthio>adenosine 36 appear to be the most interesting, have been found to have both the desired profile of activity and no hepatotoxicity, when administered po at 50, 100 or 300 mg/kg.Compounds 31, 33 and 36, orally tested at the same doses in the 15-d test, lower triglyceride and VLDL/LDL (very low density lipoprotein / low density lipoprotein) cholesterol levels by 10-33percent and 13-46percent, respectively, and increase HDL-associated cholesterol levels by 10-32percent.These molecules have been chosen for further pharmacological and toxicological evaluations. adenosine / purine / cholesterol / triglyceride / hypolipemic agent

New 8-substituted nucleoside and purine derivatives, the process for the preparation thereof and the pharmaceutical compositions containing them

New 8-substituted nucleoside and purine derivatives of the general formula: STR1 wherein R represents an amino group or an hydroxy group possibly in the corresponding keto tautomeric form, R1 is hydrogen or an amino group, R2 is hydrogen or a β-D-ribofuranosyl radical wherein the primary hydroxy group and/or the two secondary hydroxy groups may be derivatized, R3 is an optionally substituted aryl or monocyclic heteroaryl radical and, X is --O-- or --S--. The new compounds have antihyperlipaemic activity.